American Portfolios Advisors Bei Gene, Ltd. Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Bei Gene, Ltd. stock. As of the latest transaction made, American Portfolios Advisors holds 391 shares of BGNE stock, worth $88,643. This represents 0.0% of its overall portfolio holdings.

Number of Shares

391

Holding current value

$88,643

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$131.8 - $202.24 $51,533 - $79,075	391 New	391 $52.7 Million
Q2 2022 Mar 20, 2023	BUY	$121.11 - $216.05 $968 - $1,728	8 Added 2.05%	399 $64.6 Million
Q1 2022 Mar 21, 2023	BUY	$146.52 - $269.56 $2,051 - $3,773	14 Added 3.58%	405 $76.4 Million
Q4 2021 Mar 21, 2023	SELL	$248.56 - $389.34 $28,087 - $43,995	-113 Reduced 28.9%	278 $75.3 Million
Q3 2021 Mar 22, 2023	SELL	$249.6 - $403.14 $43,430 - $70,146	-174 Reduced 44.5%	217 $78.8 Million
Q2 2021 Mar 22, 2023	SELL	$292.75 - $367.01 $67,332 - $84,412	-230 Reduced 58.82%	161 $55.3 Million
Q1 2021 Mar 22, 2023	SELL	$260.64 - $382.12 $61,771 - $90,562	-237 Reduced 60.61%	154 $53.6 Million
Q4 2020 Mar 22, 2023	SELL	$221.31 - $316.61 $69,048 - $98,782	-312 Reduced 79.8%	79 $20.4 Million
Q3 2020 Mar 22, 2023	SELL	$189.18 - $286.44 $47,484 - $71,896	-251 Reduced 64.19%	140 $40.1 Million
Q2 2020 Mar 24, 2023	SELL	$123.9 - $195.41 $3,717 - $5,862	-30 Reduced 41.1%	43 $8.1 Million
Q1 2020 Mar 24, 2023	SELL	$121.84 - $173.19 $38,745 - $55,074	-318 Reduced 81.33%	73 $8.99 Million
Q4 2019 Mar 24, 2023	SELL	$115.78 - $208.34 $40,291 - $72,502	-348 Reduced 89.0%	43 $7.13 Million
Q2 2019 Mar 24, 2023	SELL	$113.99 - $146.86 $42,632 - $54,925	-374 Reduced 95.65%	17 $2.11 Million
Q1 2019 Mar 24, 2023	SELL	$122.82 - $151.83 $45,934 - $56,784	-374 Reduced 95.65%	17 $2.24 Million

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

45.1M

Call Options Held

131K

Put Options Held

95.6K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Bei Gene, Ltd. Transaction History